These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25035163)

  • 1. Viral lower respiratory tract infections and preterm infants' healthcare utilisation.
    Drysdale SB; Alcazar-Paris M; Wilson T; Smith M; Zuckerman M; Peacock JL; Johnston SL; Greenough A
    Eur J Pediatr; 2015 Feb; 174(2):209-15. PubMed ID: 25035163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhinovirus infection and healthcare utilisation in prematurely born infants.
    Drysdale SB; Alcazar-Paris M; Wilson T; Smith M; Zuckerman M; Broughton S; Rafferty GF; Peacock JL; Johnston SL; Greenough A
    Eur Respir J; 2013 Oct; 42(4):1029-36. PubMed ID: 23563263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.
    Broughton S; Roberts A; Fox G; Pollina E; Zuckerman M; Chaudhry S; Greenough A
    Thorax; 2005 Dec; 60(12):1039-44. PubMed ID: 16227330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants.
    Shefali-Patel D; Paris MA; Watson F; Peacock JL; Campbell M; Greenough A
    Eur J Pediatr; 2012 Jul; 171(7):1055-61. PubMed ID: 22302458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
    Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
    Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung function prior to viral lower respiratory tract infections in prematurely born infants.
    Drysdale SB; Wilson T; Alcazar M; Broughton S; Zuckerman M; Smith M; Rafferty GF; Johnston SL; Greenough A
    Thorax; 2011 Jun; 66(6):468-73. PubMed ID: 21447496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory viral infections in infancy and school age respiratory outcomes and healthcare costs.
    MacBean V; Drysdale SB; Yarzi MN; Peacock JL; Rafferty GF; Greenough A
    Pediatr Pulmonol; 2018 Mar; 53(3):342-348. PubMed ID: 29314779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
    Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
    Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
    Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
    Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory outcome of prematurely born infants following human rhinovirus A and C infections.
    Drysdale SB; Alcazar M; Wilson T; Smith M; Zuckerman M; Lauinger IL; Tong CY; Broughton S; Rafferty GF; Johnston SL; Greenough A
    Eur J Pediatr; 2014 Jul; 173(7):913-9. PubMed ID: 24493557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower respiratory tract illness and RSV prophylaxis in very premature infants.
    Lacaze-Masmonteil T; Truffert P; Pinquier D; Daoud P; Goldfarb G; Vicaut E; Fauroux B
    Arch Dis Child; 2004 Jun; 89(6):562-7. PubMed ID: 15155404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
    Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N
    Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RSV prophylaxis in premature infants.
    Del Vecchio A; Franco C; Del Vecchio K; Umbaldo A; Capasso L; Raimondi F
    Minerva Pediatr; 2018 Dec; 70(6):579-588. PubMed ID: 30334620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.